Translation

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Alfresa Holdings Corporation
October 31, 2025

Notice Regarding Revisions to Consolidated Performance Forecast (Prepared Based on Japan's Generally Accepted Accounting Principles (GAAP))

Due to recent performance trends and other factors, the Company has revised its consolidated performance forecast for the first half of fiscal 2025, which was announced on May 15, 2025. The revised forecast is as follows.

1. Revised Consolidated Performance Forecast for the First Half of Fiscal 2025 (April 1, 2025–September 30, 2025)

(Millions of yen)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of the parent	Earnings per share of common stock
Previous forecast (A)	1,531,800	14,000	15,300	9,100	¥50.06
Revised forecast (B)	1,529,700	16,200	17,400	11,500	¥63.24
Change (B-A)	–2,100	2,200	2,100	2,400	
Percentage change (%)	–0.1	15.7	13.7	26.4	
(Ref.) Results from the first half of the previous fiscal year (first half of fiscal 2024)	1,456,355	14,995	16,279	14,065	¥75.26

2. Reasons for Revisions

Regarding the consolidated financial results for the first half of fiscal 2025, operating profit and ordinary profit are expected to exceed the initial forecast due to a delay in the recording of a portion of selling, general and administrative expenses, in addition to reducing expenses to control costs. Profit attributable to owners of the parent is also expected to surpass the initial forecast. Additionally, extraordinary profit has been recorded in the form of a gain on the sale of investment securities in the process of reducing cross-shareholdings.

The full-year consolidated performance forecast for fiscal 2025 will be announced when we disclose our consolidated financial results for the first half of fiscal 2025, scheduled for November 6, 2025.

Note: The above forecast was prepared on the basis of available information at the time of the release of this notice. Actual performance may differ substantially from these forecasts due to various factors.

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, "we create and deliver a fresh life for all," come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, operating dispensing pharmacies, and regenerative medicine-related business. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥2.9 trillion for the fiscal year ended March 31, 2025. For more information, please see: https://www.alfresa.com/eng/